Leading Silicon Valley VC Firm in Cybersecurity, Enterprise Software, Consumer and Healthcare Closes Thirteenth Fund to Continue Successful Early-Stage Franchise
MENLO PARK, Calif.–(BUSINESS WIRE)–U.S. Venture Partners (USVP), a premier Silicon Valley venture capital firm, announced today the closing of USVP XIII, a $400M fund focused on Series A and B investments. The new fund continues USVP’s successful early-stage investment franchise, building leading companies in cybersecurity, enterprise software, consumer and healthcare.
USVP has led investments in 93 companies that completed initial public offerings and 100 more that were profitably acquired. “Our limited partners count on us to give them exposure to some of the fastest-growing and most-innovative companies in our areas of focus, and we are pleased to continue delivering that with USVP XIII,” said Rick Lewis, General Partner. “We have extended our multi-decade track record of success with exceptionally strong performance in recent years. From 2020 to present, USVP funds have distributed $1.1 billion to our investors. 2022 will mark the eleventh consecutive year in which USVP distributions to limited partners exceeded called capital.”
USVP’s strategy is to be the lead Series A or B investor in companies based in the U.S. or Israel in four core sectors: cybersecurity, enterprise software, consumer and healthcare. “USVP operates in specific sectors where we have a track record of leadership. USVP companies like Carrot Fertility, Cato Networks, Epsagon, Human Interest, Inari Medical and Pluto TV achieved leadership in large, high-growth sectors,” remarked Dafina Toncheva, General Partner. “We have had success investing in proven entrepreneurs who are in the early stages of building their companies, in sectors where the USVP team has deep domain expertise. We are proud that so many of those companies have gone on to become the undisputed leaders in their industries and markets.”
The USVP investment team—Dafina Toncheva, Jacques Benkoski, Rick Lewis, Steve Krausz, Casey Tansey, and Jonathan Root—has over 100 years of combined VC investing experience and a 3.5X track record on realizations across USVP’s four most recent fully-invested funds. “The USVP partners have both operating experience and an investment track record in their sectors of focus,” said Casey Tansey, General Partner. “This experience allows the USVP team to be true company-building partners to our management teams. We are grateful to the entrepreneurs who have chosen us as their partner as they seek to transform global industries. We also are honored to have earned the confidence of premier Limited Partners in the U.S. and around the world who have invested in USVP XIII.”
About U.S. Venture Partners
U.S. Venture Partners (USVP) is a leading Silicon Valley venture capital firm, partnering with entrepreneurs to transform their ideas into world-changing companies. USVP has invested in over 500 companies spanning four decades, including: Arkose Labs, Box, Carrot Fertility, Cato Networks, Check Point Software, Guidewire, Happy Returns, HeartFlow, HotelTonight, Human Interest, Imperva, Inari Medical, Inspire Medical Systems, Intersect ENT, Kenna, Medigate, Omada Health, Pluto TV, Standard Bariatrics, ThreatMetrix, Trunk Club, Trusteer, Yammer and Zerto. USVP focuses on early-stage start-ups that transform cybersecurity, enterprise software, consumer and healthcare. The USVP team consists of former entrepreneurs, technologists, corporate executives, and financial professionals who assist with strategy, scaling, team building, product development, and business development. USVP is based in Menlo Park, California. More information can be found at www.usvp.com.
Contacts
Dale Holladay
USVP
(650) 854-9080
pr@usvp.com
